ストックスクリーナーアプリを入手
202.37
0.70%
-1.42
プレマーケット:
202.75
0.38
+0.19%
前日終値:
$203.79
開ける：
$202.02
24時間の取引高:
989.27K
Relative Volume:
0.85
時価総額：
$29.36B
収益：
$5.54B
当期純損益:
$1.52B
株価収益率:
19.51
EPS:
10.3734
ネットキャッシュフロー:
$1.74B
1週間 パフォーマンス:
-3.47%
1か月 パフォーマンス:
-12.11%
6か月 パフォーマンス:
-19.73%
1年 パフォーマンス:
-18.28%
1日の値動き範囲:
$200.77
$203.24
1週間の範囲:
$198.61
$211.23
52週間の値動き範囲:
$198.61
$293.81
Resmed Inc Stock (RMD) Company Profile
Compare RMD vs ISRG, BDX, MDLN, ALC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RMD
Resmed Inc
|
202.37 | 29.56B | 5.54B | 1.52B | 1.74B | 10.37 |
ISRG
Intuitive Surgical Inc
|
432.27 | 152.95B | 10.58B | 3.00B | 2.83B | 8.2437 |
BDX
Becton Dickinson Co
|
144.18 | 40.64B | 21.37B | 1.41B | 3.07B | 3.9437 |
MDLN
Medline Inc
|
38.71 | 32.60B | 29.14B | 1.07B | 1.05B | 1.1956 |
ALC
Alcon Inc
|
63.44 | 31.11B | 10.63B | 819.00M | 1.59B | 1.6577 |
Resmed Inc Stock (RMD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-15 | 開始されました | JP Morgan | Overweight |
| 2025-12-16 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2025-09-18 | 開始されました | Citigroup | Buy |
| 2025-09-02 | アップグレード | CLSA | Hold → Outperform |
| 2025-07-15 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-03-19 | 開始されました | Morgan Stanley | Overweight |
| 2025-01-16 | 開始されました | Goldman | Buy |
| 2025-01-10 | 開始されました | Piper Sandler | Neutral |
| 2024-12-13 | 開始されました | Stifel | Hold |
| 2024-09-24 | 開始されました | Robert W. Baird | Outperform |
| 2024-09-18 | ダウングレード | Wolfe Research | Peer Perform → Underperform |
| 2024-09-04 | ダウングレード | Needham | Buy → Hold |
| 2024-06-25 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2024-06-24 | ダウングレード | Citigroup | Buy → Neutral |
| 2024-02-06 | 再開されました | KeyBanc Capital Markets | Overweight |
| 2023-10-27 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2023-10-12 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-10-09 | アップグレード | JP Morgan | Neutral → Overweight |
| 2023-09-29 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2023-09-06 | アップグレード | Needham | Hold → Buy |
| 2023-09-05 | ダウングレード | UBS | Buy → Neutral |
| 2023-08-01 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-05-23 | 開始されました | UBS | Buy |
| 2023-04-14 | 開始されました | Mizuho | Buy |
| 2023-01-17 | アップグレード | JP Morgan | Neutral → Overweight |
| 2022-10-28 | ダウングレード | Citigroup | Buy → Neutral |
| 2022-10-20 | アップグレード | BofA Securities | Neutral → Buy |
| 2022-10-12 | 開始されました | Jefferies | Hold |
| 2022-09-08 | アップグレード | Citigroup | Neutral → Buy |
| 2022-08-15 | ダウングレード | CLSA | Buy → Outperform |
| 2022-08-12 | ダウングレード | Citigroup | Buy → Neutral |
| 2022-08-12 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2022-08-12 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-06-06 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-04-06 | 開始されました | Wolfe Research | Outperform |
| 2022-01-31 | アップグレード | Citigroup | Neutral → Buy |
| 2022-01-31 | アップグレード | Goldman | Neutral → Buy |
| 2022-01-28 | アップグレード | RBC Capital Mkts | Underperform → Sector Perform |
| 2022-01-24 | アップグレード | BofA Securities | Underperform → Neutral |
| 2022-01-24 | アップグレード | JP Morgan | Neutral → Overweight |
| 2022-01-13 | アップグレード | CLSA | Outperform → Buy |
| 2022-01-13 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2021-12-21 | アップグレード | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-12-06 | アップグレード | Macquarie | Neutral → Outperform |
| 2021-10-22 | アップグレード | CLSA | Underperform → Outperform |
| 2021-08-02 | ダウングレード | CLSA | Outperform → Sell |
| 2021-08-02 | ダウングレード | Needham | Buy → Hold |
| 2021-07-28 | アップグレード | Jefferies | Underperform → Hold |
| 2021-07-26 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2021-07-14 | 開始されました | RBC Capital Mkts | Underperform |
| 2021-06-28 | ダウングレード | Citigroup | Buy → Neutral |
| 2021-06-22 | アップグレード | Macquarie | Neutral → Outperform |
| 2021-06-22 | 開始されました | Robert W. Baird | Neutral |
| 2021-06-21 | 繰り返されました | Needham | Buy |
| 2021-06-16 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2021-06-09 | アップグレード | CLSA | Sell → Outperform |
| 2021-05-21 | アップグレード | JP Morgan | Neutral → Overweight |
| 2021-05-11 | アップグレード | Citigroup | Neutral → Buy |
| 2021-04-30 | ダウングレード | Citigroup | Buy → Neutral |
| 2021-03-16 | アップグレード | Needham | Hold → Buy |
| 2020-11-02 | アップグレード | UBS | Neutral → Buy |
| 2020-10-30 | アップグレード | JP Morgan | Underweight → Neutral |
| 2020-10-27 | アップグレード | BofA Securities | Underperform → Neutral |
| 2020-08-07 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-06-17 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2020-05-01 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2020-05-01 | アップグレード | Oppenheimer | Perform → Outperform |
| 2020-02-18 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-03 | 開始されました | CLSA | Underperform |
| 2020-01-31 | ダウングレード | UBS | Buy → Neutral |
| 2020-01-10 | 開始されました | Oppenheimer | Perform |
| 2019-11-22 | 開始されました | KeyBanc Capital Markets | Sector Weight |
| 2019-07-29 | アップグレード | UBS | Neutral → Buy |
| 2019-07-16 | ダウングレード | UBS | Buy → Neutral |
| 2019-05-06 | アップグレード | UBS | Neutral → Buy |
| 2019-04-18 | アップグレード | JP Morgan | Underweight → Neutral |
| 2019-01-25 | ダウングレード | Goldman | Buy → Neutral |
| 2019-01-25 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2018-10-26 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2018-07-02 | 開始されました | Goldman | Buy |
すべてを表示
Resmed Inc (RMD) 最新ニュース
Swiss Life Asset Management Ltd Cuts Stake in ResMed Inc. $RMD - MarketBeat
ResMed Inc stock (AU000000RMD6): ex-dividend date approaches May 14 - AD HOC NEWS
ResMed stock (US7611521078): ex-dividend date approaches on May 14 - AD HOC NEWS
ResMed stock (US7611521078): CEO exercises options amid NYSE price drop - AD HOC NEWS
Is ResMed a Better Buy Than Stryker? - Trefis
ResMed Inc. stock rises Tuesday, outperforms market - MarketWatch
Should you buy ResMed shares at their 52-week low? - The Motley Fool Australia
ResMed stock hits 52-week low at $198.62 By Investing.com - Investing.com India
A Look at ResMed Inc (RMD) After 3.9% Decline -- GF Value $270.0 - GuruFocus
A Look at ResMed Inc (RMD) After 3.9% Decline -- GF Value $270.01 vs Price $198.76 - GuruFocus
ResMed CEO Farrell Exercises Options and Trims Stake Under 10b5-1 Plan - TipRanks
ResMed Inc. stock falls Monday, underperforms market - MarketWatch
ResMed stock hits 52-week low at $198.62 - Investing.com
ResMed Inc. stock (US7611521078): Recent price dynamics signal trading opportunities - AD HOC NEWS
ResMed (NYSE:RMD) CEO Sells $1,037,229.62 in Stock - MarketBeat
ResMed chairman and CEO Michael Farrell sells $1 million in stock - Investing.com Nigeria
Resmed Insider Sold Shares Worth $1,037,233, According to a Recent SEC Filing - marketscreener.com
ResMed (NYSE: RMD) CEO sells 4,991 shares under 10b5-1 plan - Stock Titan
Should you continue to hold Resmed stock in your portfolio? - MSN
ResMed Inc stock (AU000000RMD6): Sleep apnea and respiratory care leader posts strong growth outlook - AD HOC NEWS
ResMed (NYSE:RMD) Could Be A Buy For Its Upcoming Dividend - Yahoo Finance
ResMed Inc. stock: Earnings beat but shares slip on guidance concerns - AD HOC NEWS
Number of shareholders of ResMed Inc. CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh – LSX:935168 - TradingView
ResMed, Inc. Experiences Valuation Adjustment Amid Competitive Pharmaceuticals Sector Landscape - Markets Mojo
Mitsubishi UFJ Asset Management Co. Ltd. Increases Holdings in ResMed Inc. $RMD - MarketBeat
ResMed Inc. $RMD Shares Sold by Strs Ohio - MarketBeat
RMD Stock Price, Quote & Chart | RESMED INC (NYSE:RMD) - ChartMill
ResMed expects FY 2026 gross margin of 62%-63% as it plans $175M+ Q4 buybacks and targets June 1 close for $340M Noctrix deal - MSN
ResMed Inc. stock falls Thursday, underperforms market - MarketWatch
[144] RESMED INC SEC Filing - Stock Titan
QRG Capital Management Inc. Has $5.39 Million Stock Holdings in ResMed Inc. $RMD - MarketBeat
ResMed’s Q1 Earnings Call: Our Top 5 Analyst Questions - The Globe and Mail
Resmed boosts sleep health portfolio with Noctrix buy - BioWorld News
ResMed Stock Is Down 22% in 2026: Here’s Why Analysts Still Sees $256 Fair Value - TIKR.com
Piper Sandler Maintains ResMed(RMD.US) With Hold Rating, Cuts Target Price to $233 - Moomoo
Swedbank AB Has $265.55 Million Holdings in ResMed Inc. $RMD - MarketBeat
Harel Insurance Investments & Financial Services Ltd. Decreases Stock Holdings in ResMed Inc. $RMD - MarketBeat
Wall Street's insights into key metrics ahead of ResMed (RMD) Q3 earnings - MSN
ResMed, Inc. Hits New 52-Week Low at USD 210.67 - Markets Mojo
Resmed enters merger agreement to acquire Noctrix Health for $340 million - MassDevice
9 Stocks That Could Defy the ’Sell in May and Go Away’ Trend This Time - Investing.com
Resmed integrating AI for sleep apnea treatment - Yahoo Finance
Here's Why ResMed (RMD) is a Strong Growth Stock - Yahoo Finance
Birch Capital Management LLC Reduces Stock Holdings in ResMed Inc. $RMD - MarketBeat
Stifel Nicolaus Adjusts ResMed Price Target to $235 From $265 - Moomoo
Ord Minnett Reaffirms Their Buy Rating on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD) - The Globe and Mail
[Form 3] RESMED INC Initial Statement of Beneficial Ownership - Stock Titan
ResMed (RMD) CFO Brett Sandercock reports direct holding of 83,495 shares - Stock Titan
ResMed Inc. stock rises Monday, outperforms market - MarketWatch
ResMed Inc. (RMD) Stock Analysis: Exploring a 31.99% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews
ResMed announces CFO succession - MSN
Resmed Inc (RMD) 財務データ
収益
当期純利益
現金流量
EPS
0.53%
0.42%
大文字化:
|
ボリューム (24 時間):